Entrapped doxorubicin nanoparticles for the treatment of metastatic anoikis-resistant cancer cells

Cancer Letters

Volumn 332, Issue 1, 2013, Pages 110-119

  Lee, Hohyeon ^a   Park, Sunyoung ^a   Kim, Jong Bin ^b   Kim, Jungwook ^a   Kim, Hyuncheol ^a  

^a Sogang University   (South Korea)

^b Real Cosmetic Surgery Clinic   (South Korea)

Author keywords

Anoikis resistance; Chemoresistance; Doxorubicin; Human serum albumin nanoparticle; MCF 7; MDA MB 231; Metastasis; Nanomedicine; Side populations

Indexed keywords

DOXORUBICIN; HUMAN SERUM ALBUMIN; NANOPARTICLE;

ANOIKIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; HUMAN; HUMAN CELL; NANOFABRICATION; PRIORITY JOURNAL; SIDE POPULATION CELL;

ANOIKIS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MCF-7 CELLS; MICROSCOPY, CONFOCAL; NANOPARTICLES; NEOPLASTIC STEM CELLS; SERUM ALBUMIN; SIDE-POPULATION CELLS; TIME FACTORS;

EID: 84875275119     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.021     Document Type: Article

References (49)

1. Kriege M., Brekelmans C.T.M., Boetes C., Besnard P.E., Zonderland H.M., Obdeijn I.M., Manoliu R.A., Kok T., Peterse H., Tilanus-Linthorst M.M.A., Muller S.H., Meijer S., Oosterwijk J.C., Beex L.V.A.M., Tollenaar R.A.E.M., de Koning H.J., Rutgers E.J.T., Klijn J.G.M., Screeni M.R.I. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. New Engl. J. Med. 2004, 351:427-437.
2. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
3. Ullah M.F. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pacific J. Cancer Prevention: APJCP 2008, 9:1-6.
4. Germann U.A., Pastan I., Gottesman M.M. P-glycoproteins: mediators of multidrug resistance. Semin. Cell Biol. 1993, 4:63-76.
5. Kim J.B., Yu J.H., Ko E., Lee K.W., Song A.K., Park S.Y., Shin I., Han W., Noh D.Y. The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine 2010, 17:436-440.
6. Normanno N., De Luca A., Bianco C., Maiello M.R., Carriero M.V., Rehman A., Wechselberger C., Arra C., Strizzi L., Sanicola M., Salomon D.S. Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J. Cell. Physiol. 2004, 198:31-39.
7. Reginato M.J., Mills K.R., Paulus J.K., Lynch D.K., Sgroi D.C., Debnath J., Muthuswamy S.K., Brugge J.S. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat. Cell Biol. 2003, 5:733-740.
8. Liotta L.A., Kohn E. Anoikis: cancer and the homeless cell. Nature 2004, 430:973-974.
9. Frisch S.M., Ruoslahti E. Integrins and anoikis. Curr. Opin. Cell Biol. 1997, 9:701-706.
10. Simpson C.D., Anyiwe K., Schimmer A.D. Anoikis resistance and tumor metastasis. Cancer Lett. 2008, 272:177-185.
11. Kim Y.N., Koo K.H., Sung J.Y., Yun U.J., Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int. J. Cell Biol. 2012, 2012:306879.
12. Green M.R., Manikhas G.M., Orlov S., Afanasyev B., Makhson A.M., Bhar P., Hawkins M.J. Abraxane((R)), a novel Cremophor((R))-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006, 17:1263-1268.
13. O'Shaughnessy J.A. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin. Breast Cancer 2003, 4:318-328.
14. McNeil S.E. Unique benefits of nanotechnology to drug delivery and diagnostics. Methods Mol. Biol. 2011, 697:3-8.
15. Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updates 2011, 14:150-163.
16. Sumer B., Gao J. Theranostic nanomedicine for cancer. Nanomedicine (London) 2008, 3:137-140.
17. Liu Y., Miyoshi H., Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer 2007, 120:2527-2537.
18. Shuhendler A.J., Cheung R.Y., Manias J., Connor A., Rauth A.M., Wu X.Y. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res. Treat. 2010, 119:255-269.
19. Wong H.L., Rauth A.M., Bendayan R., Manias J.L., Ramaswamy M., Liu Z., Erhan S.Z., Wu X.Y. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm. Res. 2006, 23:1574-1585.
20. Sharma R.I., Pereira M., Schwarzbauer J.E., Moghe P.V. Albumin-derived nanocarriers: substrates for enhanced cell adhesive ligand display and cell motility. Biomaterials 2006, 27:3589-3598.
21. Low K., Wacker M., Wagner S., Langer K., von Briesen H. Targeted human serum albumin nanoparticles for specific uptake in EGFR-expressing colon carcinoma cells. Nanomedicine 2011, 7:454-463.
22. Wagner S., Rothweiler F., Anhorn M.G., Sauer D., Riemann I., Weiss E.C., Katsen-Globa A., Michaelis M., Cinatl J., Schwartz D., Kreuter J., von Briesen H., Langer K. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 2010, 31:2388-2398.
23. Kang S., Kim M., Park H., Kim E. Expression profiles of Streptomyces doxorubicin biosynthetic gene cluster using DNA microarray system. Korean J. Biotechnol. Bioeng. 2005, 20:220-227.
24. Morozevich G.E., Kozlova N.I., Preobrazhenskaya M.E., Ushakova N.A., Eltsov I.A., Shtil A.A., Berman A.E. The role of beta1 integrin subfamily in anchorage-dependent apoptosis of breast carcinoma cells differing in multidrug resistance. Biochemistry (Mosc) 2006, 71:489-495.
25. White D.E., Kurpios N.A., Zuo D., Hassell J.A., Blaess S., Mueller U., Muller W.J. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004, 6:159-170.
26. Huang C., Park C.C., Hilsenbeck S.G., Ward R., Rimawi M.F., Wang Y.C., Shou J., Bissell M.J., Osborne C.K., Schiff R. Beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res.: BCR 2011, 13:R84.
27. Kozlova N.I., Morozevich G.E., Chubukina A.N., Shtil A.A., Berman A.E. Expression of integrins, anchorage dependent apoptosis and invasiveness of multidrug resistant human breast carcinoma cells. EXCLI J. 2004, 68-81.
28. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H., Sorrentino B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7:1028-1034.
29. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat. Rev. Cancer 2006, 6:449-458.
30. van der P., Vloedgraven H., Papapoulos S., Lowick C., Grzesik W., Kerr J., Robey P.G. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab. Invest. 1997, 77:665-675.
31. Manzotti M., Dell'Orto P., Maisonneuve P., Fornaro M., Languino L.R., Viale G. Down-regulation of beta(1C) integrin in breast carcinomas correlates with high proliferative fraction, high histological grade, and larger size. Am. J. Pathol. 2000, 156:169-174.
32. Yao E.S., Zhang H., Chen Y.Y., Lee B., Chew K., Moore D., Park C. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007, 67:659-664.
33. N.I. Kozlova, G.E. Morozevich, A.N. Chubukina, A.A. Shtil, A.E. Berman, Expression of integrins, anchorage dependent apoptosis and invasiveness of multidrug resistant human breast carcinoma cells. EXCLI J. (2004) 68-81.
34. Aoudjit F., Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother. Res. Pract. 2012, 2012:283181.
35. Park C.C., Zhang H., Pallavicini M., Gray J.W., Baehner F., Park C.J., Bissell M.J. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 2006, 66:1526-1535.
36. Liu S.Q., Tong Y.W., Yang Y.Y. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N, N-dimethylacrylamide)-b-poly(D,L-lactide-co-glyco lide) with varying compositions. Biomaterials 2005, 26:5064-5074.
37. Manocha B., Margaritis A. Controlled release of doxorubicin from doxorubicin/gamma-polyglutamic acid ionic complex. J. Nanomater. 2010, 2010:780171.
38. Tiruppathi C., Song W., Bergenfeldt M., Sass P., Malik A.B. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J. Biol. Chem. 1997, 272:25968-25975.
39. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Controlled Release 2008, 132:171-183.
40. Desai N., Trieu V., Yao Z. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 2006, 12(4):1317-1324.
41. Gong G.M., Zhi F., Wang K.K., Tang X.L., Yuan A., Zhao L.L., Ding D.W., Hu Y.Q. Fabrication of a nanocarrier system through self-assembly of plasma protein and its tumor targeting. Nanotechnology 2011, 22:295603.
42. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
43. Ejendal K.F., Hrycyna C.A. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr. Protein Pept. Sci. 2002, 3:503-511.
44. Burkert J., Otto W.R., Wright N.A. Side populations of gastrointestinal cancers are not enriched in stem cells. J. Pathol. 2008, 214:564-573.
45. Ho M.M., Ng A.V., Lam S., Hung J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007, 67:4827-4833.
46. Ko E., Han W., Noh D.Y. Reduced self-renewal ability and drug resistance by inhibition of notch-4 and ABCG2 in anoikis-resistant MDA-MB-231 breast cancer cells. Cancer Res. 2009, 69:318s.
47. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
48. Singh R., Lillard J.W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 2009, 86:215-223.
49. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release 2000, 65:271-284.